Personalized cancer treatments struggling to overcome patient deaths, severe side effects

dividing cancer cells
Image via Singularity Hub.

The idea is tantalizing: Reengineer a patient’s own immune cells to attack the cancer that’s killing her. Scientists have proven it can be done, curing patients of…blood cancers.

But faith in this approach, dubbed CAR-T immunotherapy, has been [recently] shaken….

To be sure, there’s still excitement in the field.


“I think the story line today is, CAR-T is really walking a fine line,” said Brad Loncar…“A year ago, there was definitely exuberance. But now, we’re on the precipice of people pulling back.”

Scaling up is a tricky prospect for CAR-T therapy. Increasing the capacity to manufacture a standard biologic drug might involve bumping up the size of a bioreactor so it can pump out…5,000 liters…But CAR-T therapy is so highly personalized that manufacturers have to effectively build 5,000 one-liter bioreactors….

“I think it’ll take us years, though certainly not decades, to get to the point where we have near-complete automation,” [Bruce] Levine said.


[C]ell therapies will need both clinical success and commercialization to keep up the momentum, Loncar said.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: Hurdles abound in race to bring customized cancer treatments to masses

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend